New CAR-T therapy targets two proteins to fight Hard-to-Treat myeloma
NCT ID NCT07196124
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This early-phase study tests a new type of cell therapy (CAR-T) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It is for people whose multiple myeloma has come back or stopped responding to treatment. The main goals are to check safety and find the right dose in 12 adults aged 18-85.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.